Scarica l'app Stockscreener
2.19
9.50%
0.19
Dopo l'orario di chiusura:
2.17
-0.02
-0.91%
Precedente Chiudi:
$2.00
Aprire:
$1.95
Volume 24 ore:
1.19M
Relative Volume:
1.93
Capitalizzazione di mercato:
$232.58M
Reddito:
-
Utile/perdita netta:
$-31.64M
Rapporto P/E:
-5.1822
EPS:
-0.4226
Flusso di cassa netto:
$-13.98M
1 W Prestazione:
+26.59%
1M Prestazione:
-38.57%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.92
$2.20
Intervallo di 1 settimana:
$1.71
$2.20
Portata 52W:
$1.70
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Nome
Nervgen Pharma Corp
Settore
Industria
Telefono
-
Indirizzo
-
Compare NGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
2.19 | 197.54M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | H.C. Wainwright | Buy |
Nervgen Pharma Corp Borsa (NGEN) Ultime notizie
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
NervGen Pharma Corp. Financial Disclosures & SEC Filings - TradingView
NervGen Pharma (NGEN) Investor Relations, Earnings Summary & Outlook - Quartr
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - GuruFocus
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
NervGen stock initiated at Buy by TD Cowen ahead of phase 3 trial - Investing.com UK
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
NGENNervGen Pharma Corp. stock news, filings & ratings - Quantisnow
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - TipRanks
United StatesMintz Advises On NervGen Pharma’s $60 Million Public Offering - Mondaq
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors - TipRanks
Biopharma Company Reveals High-Impact SCI Recovery Gains - Streetwise Reports
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
NervGen Pharma Company Profile & Introduction - Moomoo
These stocks have an unusual volume in today's session - ChartMill
NervGen reports positive gait analysis data for NVG-291 trial - grafa.com
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Australia
NervGen Pharma Corp. Announces Positive Independent Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In Phase 1b/2a CONNECT SCI Study - marketscreener.com
NervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic Tetraplegia - Quiver Quantitative
Spinal cord injury trial: NervGen drug improves walking control - Stock Titan
Assessing NervGen Pharma (NasdaqCM:NGEN) Valuation After Its $60 Million Follow On Equity Offering - Sahm
NervGen Pharma Raises Capital to Advance Therapy for Spinal Cord Injury - techcouver.com
NervGen launches underwritten public offering of shares and warrants - MSN
NGEN Slides As NervGen Pharma Dilution Hits Share Price - timothysykes.com
NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68 - MSN
NervGen Pharma Prices $60 Million Share Offering - Moomoo
HC Wainwright & Co. initiates coverage of NervGen Pharma (NGEN) with buy recommendation - MSN
NGEN: Joint Book Runners for Recent Offering Announced - GuruFocus
NervGen Pharma Shares Continue Sliding on Size of $60 Million Share Sale - Moomoo
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Biggest stock movers Friday: Quantum computing stocks, WDAY, ZM, and more - Seeking Alpha
NervGen Pharma stock tumbles on dilutive share offering By Investing.com - Investing.com India
NervGen Pharma, Medline, sociétés minières d'argent - TradingView
NervGen Pharma stock tumbles on dilutive share offering - Investing.com
Nervgen Pharma Corp Azioni (NGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):